Idexx Laboratories has steadily increased its scale and reach in the veterinary diagnostic lab business to dig a narrow moat. It is well-positioned to benefit from two key trends. First, pet ownership ...
Idexx Laboratories (IDXX) reported $1.11 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 10.6%. EPS of $3.63 for the same period compares to $2.44 a year ...
Hosted on MSN
Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Wall Street expects a year-over-year increase in earnings on higher revenues when Idexx Laboratories (IDXX) reports results for the quarter ended September 2025. While this widely-known consensus ...
For the quarter ended September 2024, Idexx Laboratories (IDXX) reported revenue of $975.54 million, up 6.6% over the same period last year. EPS came in at $2.80, compared to $2.53 in the year-ago ...
AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology cases The global launch of the IDEXX (IDXX) inVue Dx ...
Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive ...
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026 ...
IDEXX Laboratories, Inc. IDXX is set to release second-quarter 2025 results on Aug. 4, before the opening bell. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results